Assignee
LENTIGEN TECH INC
US·35 granted patents·20 pending applications·149 citations·filing 2016–2025
Top patents by PatentIndex Score
55 records- 0197US10844128B2Compositions and methods for treating cancer with anti-CD123 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Nov 24, 2020·20 cites·11 claims
- 0297US10442867B2Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 15, 2019·17 cites·7 claims
- 0397US10428141B2Compositions and methods for treating cancer with anti-ROR1 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 1, 2019·15 cites·13 claims
- 0496US11242389B2Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Feb 8, 2022·5 cites·20 claims
- 0596US10183993B2Compositions and methods for treating cancer with anti-mesothelin immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Jan 22, 2019·11 cites·27 claims
- 0695US11208455B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2019·Granted Dec 28, 2021·6 cites·8 claims
- 0795US10689431B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2018·Granted Jun 23, 2020·8 cites·9 claims
- 0895US10501539B2Compositions and methods for treating cancer with anti-CD19 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Dec 10, 2019·8 cites·6 claims
- 0995US10426797B2Compositions and methods for treating cancer with anti-CD33 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 1, 2019·19 cites·10 claims
- 1093US11103533B2Compositions and methods for treating cancer with anti-CD38 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Aug 31, 2021·7 cites·13 claims
- 1193US10639329B2Method to treat cancer with engineered T-cellsLENTIGEN TECH INC·Filed 2016·Granted May 5, 2020·12 cites·6 claims
- 1293US10550179B2Compositions and methods for treating cancer with anti-mesothelin immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Feb 4, 2020·6 cites·18 claims
- 1392US11052112B2Compositions and methods for treating cancer with anti-BCMA immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Jul 6, 2021·5 cites·9 claims
- 1489US11453712B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2017·Granted Sep 27, 2022·2 cites·8 claims
- 1588US11590169B1Compositions and methods for treating cancer with anti-CD123 immunotherapyLENTIGEN TECH INC·Filed 2022·Granted Feb 28, 2023·2 cites·20 claims
- 1687US11453719B2Compositions and methods for treating cancer with anti-ROR1 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Sep 27, 2022·2 cites·19 claims
- 1787US2024043497A1Compositions and Methods for Treating Cancer with DuoCARsLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 1887US2025367291A1Compositions and Methods for Treating Cancer with DuoCARsLENTIGEN TECH INC·Filed 2025·Application pending·0 cites
- 1986US11802142B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2020·Granted Oct 31, 2023·1 cites·7 claims
- 2086US2024025962A1Compositions and methods for treating cancer with duocarsLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 2184US10894819B2Compositions and methods for treating HIV/AIDS with immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Jan 19, 2021·2 cites·18 claims
- 2282US2022281946A1Compositions and Methods for Treating Cancer with DuoCARsLENTIGEN TECH INC·Filed 2022·Application pending·0 cites
- 2381US12365718B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2021·Granted Jul 22, 2025·0 cites·8 claims
- 2481US11464801B2Compositions and methods for treating cancer with anti-CD33 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Oct 11, 2022·1 cites·15 claims
- 2580US12540179B2Compositions and methods for treating cancer with anti-ROR1 immunotherapyLENTIGEN TECH INC·Filed 2022·Granted Feb 3, 2026·0 cites·13 claims
- 2680US2025084166A1Compositions and Methods for Treating Cancer with Anti-CD19/CD22 ImmunotherapyLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 2780US2024067724A1Compositions and Methods for Treating Cancer with Anti-CD19 ImmunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 2879US2024108706A1Compositions and Methods for Treating Cancer with Anti-CD22 ImmunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 2979US2024150773A1Chimeric Antigen Receptors and Methods of UseLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 3079US2025090631A1Method to Treat Cancer with Engineered T-CellsLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 3178US2024309102A1Compositions and Methods for Treating Cancer with Anti-CD123 ImmunotherapyLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 3278US2024368256A1Compositions and methods for treating hiv/aids with immunotherapyLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 3377US2024034802A1Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 3477US2026070978A1Compositions and Methods for Treating Cancer with Anti-CD19/CD22 ImmunotherapyLENTIGEN TECH INC·Filed 2025·Application pending·0 cites
- 3576US12371490B2Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapyLENTIGEN TECH INC·Filed 2022·Granted Jul 29, 2025·0 cites·27 claims
- 3676US11905515B2Chimeric antigen receptors and methods of useLENTIGEN TECH INC·Filed 2019·Granted Feb 20, 2024·0 cites·2 claims
- 3776US2026015403A1Compositions and methods for treating cancer with anti-bcma immunotherapyLENTIGEN TECH INC·Filed 2025·Application pending·0 cites
- 3875US11708408B2Compositions and methods for treating cancer with anti-CD19 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Jul 25, 2023·0 cites·17 claims
- 3974US2023241103A1Compositions and Methods for Treating Cancer with Anti-CD33 ImmunotherapyLENTIGEN TECH INC·Filed 2022·Application pending·0 cites
- 4072US12037403B2Compositions and methods for treating cancer with anti-CD123 immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Jul 16, 2024·0 cites·8 claims
- 4172US11680103B2Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Jun 20, 2023·0 cites·6 claims
- 4271US12391958B2Compositions and methods for treating cancer with anti-CD38 immunotherapyLENTIGEN TECH INC·Filed 2021·Granted Aug 19, 2025·0 cites·21 claims
- 4371US12391740B2Compositions and methods for treating cancer with anti-BCMA immunotherapyLENTIGEN TECH INC·Filed 2021·Granted Aug 19, 2025·0 cites·23 claims
- 4470US12122831B2Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Oct 22, 2024·0 cites·16 claims
- 4570US12024554B2Compositions and methods for treating HIV/AIDS with immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Jul 2, 2024·0 cites·15 claims
- 4670US11497770B2Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapyLENTIGEN TECH INC·Filed 2021·Granted Nov 15, 2022·0 cites·5 claims
- 4770US2023256020A1Compositions and Methods for Treating Cancer with TSLPR-CD19 or TSLPR-CD22 ImmunotherapyLENTIGEN TECH INC·Filed 2022·Application pending·0 cites
- 4870US2024307448A1Compositions and methods for treating cancer with self-driving chimeric antigen receptorsLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 4968US11970528B2Compositions and methods for treating cancer with anti-mesothelin immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Apr 30, 2024·0 cites·18 claims
- 5066US12193995B2Method to treat cancer with engineered T-cellsLENTIGEN TECH INC·Filed 2020·Granted Jan 14, 2025·0 cites·12 claims
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when LENTIGEN TECH INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →